Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)

被引：53

作者：

Abou-Alfa, Ghassan K.

Niedzwieski, Donna

Knox, Jennifer J.

Kaubisch, Andreas

Posey, James

Tan, Benjamin R.

Kavan, Petr

Goel, Rakesh

Lammers, Philip Edward

Bekaii-Saab, Tanios S.

Tam, Vincent Channing

Rajdev, Lakshmi

Kelley, Robin Kate

Siegel, Abby B.

Balletti, Jennifer

Harding, James J.

Howard, Lawrence Schwartz

Goldberg, Richard M.

Bertagnolli, Monica M.

Venook, Alan P.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Duke Univ, Durham, NC USA

[4] Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Montefiore Med Ctr, New York, NY USA

[6] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA

[7] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[8] McGill Univ, Montreal, PQ, Canada

[9] Ottawa Hosp, Ottawa, ON, Canada

[10] Meharry Med Coll, Nashville, TN 37208 USA

[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[12] Tom Baker Canc Clin, Calgary, AB, Canada

[13] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA

[14] Univ Calif San Francisco, San Francisco, CA 94143 USA

[15] Columbia Univ, Med Ctr, New York, NY USA

[16] Columbia Univ, New York Presbyterian Hosp, Med Ctr, New York, NY USA

[17] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA

[18] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.4003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

4003

引用

页数：2